Abstract 2870: Dose selection investigations and combination strategies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate
Snell, Daniel, Gunde, Tea, Warmuth, Stefan, Lichtlen, Peter, Liu, Linlin, Teng, Shu-wen, Zhang, Lan, Pan, ChaoHsuan, Li, Peiqi, Tietz, Julia, Brock, Matthias, Simonim, Alexandre, Hess, Christian, Weinert, Christopher, Johansson, Maria, Chatterjeee, Bithi, Bassler, Nicole, Kirk, Niels, Mendes, Catia, Heiz, Robin, Flueckiger, Naomi, Diem, Dania, Mahler, Dana, Wickihalder, Belinda, Muntwiler, Simone, Wagen, Sandro, vom Baur, Elmar, Tse, Archie N., Urech, David
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article